Carlsquare successfully advised ROTOP Pharmaka, a leading manufacturer and CDMO of radiopharmaceuticals for diagnostics and therapy, on securing strategic growth financing from GENUI and SHS Capital.
Founded in 2000 and headquartered in Dresden-Rossendorf, ROTOP Pharmaka develops and manufactures radiopharmaceutical products and radioactive ready-to-use patient doses, increasingly utilized for diagnostic and therapeutic purposes in nuclear medicine, such as cancer treatment. The company’s rapidly expanding CDMO services provide innovative solutions for next-generation radiopharmaceutical pairs in theranostics.
GENUI is a private investment firm based in Hamburg/Germany. It was founded in 2014 by renowned entrepreneurs and experienced investment professionals, who have been investing in companies for over two decades and supporting them on their growth paths. GENUI follows the approach of “Good Entrepreneurship”, combining attractive returns and positive impact. The more than 30 GENUI entrepreneurs (founders and owners of companies such as BioNTech, Fressnapf, Adecco, Cancom and others) are actively and personally involved in all stages of the investment process. The focus of GENUI is on investments in market leaders in energy transition, health and digitalization.
SHS Capital is a private equity firm specializing in healthcare investments in life sciences, medical technology, diagnostics, digital health, and industrial biotechnology companies across the DACH, Benelux, and Nordics regions. With its investments, SHS aims at shaping European healthcare champions in their respective segments via expansion financing, shareholder changes, and succession situations.
The growing demand for radiopharmaceuticals, driven by their medical and economic success and significant investments by biotech and pharmaceutical companies, has created a rapidly expanding market. High entry barriers and limited manufacturing capacities present an attractive opportunity for ROTOP to solidify its position as a leading CDMO and CCO service partner with specialized expertise and infrastructure.
“We are pleased to have found the right partner in GENUI and SHS Capital to support us in our next phase of growth and expansion. We extend our sincere gratitude to Dr. Drax, Graf Stauffenberg, and the Carlsquare Team for their extensive expertise and outstanding guidance throughout the entire process. We deeply appreciate Carlsquare’s profound expertise and genuine empathy.” – Jens Junker, CEO and shareholder, ROTOP Pharmaka GmbH
“ROTOP’s unique positioning in a very dynamically growing market led us to this investment. We are looking forward to supporting the management in their next big steps together with SHS.” – Dr. Oliver Serg, GENUI
“We see great growth potential for the company as there is a clear demand for additional CDMO services in the radiopharmaceutical sector. We have been monitoring this market closely for a year and a half and are seeing an increase in financing and acquisitions of pharma companies. We hope our investment in ROTOP will significantly support an important growth phase in the field of radiodiagnostics and radiotherapeutics.” – Dr. Cornelius Maas, Partner, SHS
Carlsquare acted as the exclusive advisor to ROTOP Pharmaka GmbH.
